|
|
Blood, 15 May 2004, Vol. 103, No. 10, pp. 3635-3643.
Prepublished online as a Blood First Edition Paper on November 20, 2003; DOI 10.1182/blood-2003-09-3081.

Submitted September 8, 2003
Accepted November 12, 2003
Bone loss following hematopoietic stem cell transplantation: a long-term follow-up
Claudia M S Schulte* and Dietrich W Beelen
Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
* Corresponding author; email: claudia.schulte{at}uni-essen.de.
Transplantation-associated bone loss is a well-known phenomenon, however effects of haematopoietic stem cell transplantation are insufficiently characterized. We conducted a prospective, unicentric long-term follow-up in 280 patients undergoing allogeneic HSCT. Bone mineral density was measured before transplantation and then yearly for at least 4 years. Patients received vitamin D plus calcium until steroid withdrawal. Mean baseline BMD was normal. We demonstrated significant bone loss with nadir BMD at month 6 for the spine and at month 24 for total body and femoral neck. Average annual bone loss was 0.6 % for spine, 0.4 % for total body, 2.3 % for femoral neck and 3.5% for Wards triangle. While spine and total body BMD returned to baseline, bone loss at femoral neck sites was attenuated, but BMD did not return to baseline until month 48 (p< 0.0001 for femoral neck and Wards triangle). Univariate factor analysis of 15 potential risk factors for rapid bone loss revealed a positive correlation of bone loss with steroid and cyclosporine A use, baseline BMD and loss of muscle mass (overwhelming power of steroid use in multifactor analysis). Such rapid BMD changes probably increase fracture risk consecutive to irreversible microarchitectural changes even if osteodensitometry shows long-term recovery.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Tauchmanova, A. Colao, G. Lombardi, B. Rotoli, and C. Selleri
REVIEW: Bone Loss and Its Management in Long-Term Survivors from Allogeneic Stem Cell Transplantation
J. Clin. Endocrinol. Metab.,
December 1, 2007;
92(12):
4536 - 4545.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Petryk, T. L. Bergemann, K. M. Polga, K. J. Ulrich, S. K. Raatz, D. M. Brown, L. L. Robison, and K. S. Baker
Prospective Study of Changes in Bone Mineral Density and Turnover in Children after Hematopoietic Cell Transplantation
J. Clin. Endocrinol. Metab.,
March 1, 2006;
91(3):
899 - 905.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Syrjala, S. L. Langer, J. R. Abrams, B. E. Storer, and P. J. Martin
Late Effects of Hematopoietic Cell Transplantation Among 10-Year Adult Survivors Compared With Case-Matched Controls
J. Clin. Oncol.,
September 20, 2005;
23(27):
6596 - 6606.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kananen, L. Volin, K. Laitinen, H. Alfthan, T. Ruutu, and M. J. Valimaki
Prevention of Bone Loss after Allogeneic Stem Cell Transplantation by Calcium, Vitamin D, and Sex Hormone Replacement with or without Pamidronate
J. Clin. Endocrinol. Metab.,
July 1, 2005;
90(7):
3877 - 3885.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Tauchmanova, P. Ricci, B. Serio, G. Lombardi, A. Colao, B. Rotoli, and C. Selleri
Short-Term Zoledronic Acid Treatment Increases Bone Mineral Density and Marrow Clonogenic Fibroblast Progenitors after Allogeneic Stem Cell Transplantation
J. Clin. Endocrinol. Metab.,
February 1, 2005;
90(2):
627 - 634.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|